Recent advances in managing triple-negative breast cancers
نویسنده
چکیده
Triple-negative breast cancer (TNBC) has been recently recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach compared with other breast cancer subgroups. Because TNBC is defined by the absence of a target (either hormone receptors or HER-2), conventional cytotoxic therapy is still the mainstay of treatment. This report focuses on the current state and recent advances in managing TNBC.
منابع مشابه
Future of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?
Triple negative breast cancer (TNBC): challenges and solutions via the immune cells TNBC is one of the most complicated types of breast cancer to treat. It is generally diagnosed based on the absence of three receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) and is thus defined as a triple negative. TNBC is often more aggressive with lower survival rates...
متن کاملTreatment options for patients with triple-negative breast cancer
Breast cancer is a heterogeneous disease composed of different subtypes, characterized by their different clinicopathological characteristics, prognoses and responses to treatment. In the past decade, significant advances have been made in the treatment of breast cancer sensitive to hormonal treatments, as well as in patients whose malignant cells overexpress or amplify HER2. In contrast, mainl...
متن کاملTriple negative and basal-like breast cancer: one or many diseases? Implications for surgical pathologists
Take home messages The majority of basal-like breast cancers have a triple negative phenotype and the vast majority of triple negative cancers display a basal-like transcriptome, however the two are not synonymous. Basal-like and triple negative breast cancers comprise a heterogeneous group of diseases, which are characterised by a constellation of morphological features. Not all basal-like and...
متن کاملDifferent prognostic factors correlate with Bcl-2 expression among triple negative and non-triple negative breast cancers.
BACKGROUND Prognostication of breast cancer using clinico-pathologic variables, although useful, remains imperfect. Recent research has focused on finding new markers of prognosis using gene expression profiling. Panels of proteins assessed by immunohistochemistry might also be useful in this regard. This study focused on Bcl-2 protein expression in triple-negative (TNBC) and non- triple-negati...
متن کاملStatin-induced molecular mechanisms of breast cancer cell death: Recent developments
Although drugs like doxorubicin, tamoxifen and herceptin are widely employed in breast cancer therapy, they are known to cause side effects such as cardio-toxicity, endometrial cancer and congestive heart failure respectively. Treatment of triple negative breast cancer (TNBC) is still challenging for clinicians and researchers, as most of the patients do not respond to traditional chemotherapeu...
متن کامل